With a FDA Breakthrough Therapy Designation a competent management would have had the market believe RVX was worth multiples of that $4.60 strike price and we'd be getting those warrants exercised for financing dollars at that much-less-dilutive price instead of a 20-times-more-dilutive financing at the current $0.20.  How this management could justify paying themselves off of our backs with riddiculously priced RSOs (a result of their own abysmal performance) is just mindboggling, demoralizing. 
JMHO